Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BRIEF-Ceapro Inc Provides Update On Development Of An Inhalable Therapeutic For Covid-19

Published 2020-08-18, 08:36 a/m
Updated 2020-08-18, 08:42 a/m

Aug 18 (Reuters) - Ceapro Inc CZO.V :

* CEAPRO INC. PROVIDES UPDATE ON DEVELOPMENT OF AN INHALABLE THERAPEUTIC FOR COVID-19

* CEAPRO - IN-VITRO STUDY WITH HUMAN CELL LINES SHOWED PGX-YBG OBTAINED FROM DIFFERENT SOURCES EXHIBITED SIGNIFICANT STIMULATORY EFFECT ON HUMAN IMMUNE RESPONSE

* CEAPRO INC - EXPECTS PGX-YBG WILL STIMULATE HUMAN IMMUNE RESPONSE ONCE INHALED INTO LUNGS & POTENTIALLY PREVENT REACTIONS LIKE CYTOKINE STORM

* CEAPRO INC - RESULTS DEMONSTRATED IN IN-VITRO STUDY WERE CONSISTENT WITH RESULTS SEEN IN PRELIMINARY BIOLOGICAL STUDY

* CEAPRO - PREPARATIONS OF A PHASE 1/2 CLINICAL TRIAL PROTOCOL TO BE COMMENCED IMMEDIATELY, PLANNED TO BE SUBMITTED TO HEALTH AUTHORITIES DURING Q4 2020

* CEAPRO - FIRST MILESTONE TO OPTIMIZE SIZE & MORPHOLOGY OF BEST PGX-YBG FOR IMMUNOMODULATION WAS FULLY ACHIEVED

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.